抗癌药物专利信息的法律状态分析

Information Analysis of Legal Status of the Anticancer Drug Patent

目的:为抗癌药物制造企业的专利申请及衡量研发差距、专利质量等提供参考。方法:以抗癌药物中国专利为研究对象,检索中国知识产权网专利信息服务平台1985-04-01-2012-06-29上的所有抗癌药物中国专利的法律状态数据,主要从专利的授权、专利的失效及原因、专利的寿命3个方面进行法律状态信息分析。结果与结论:共检索到17 065项抗癌药物中国专利,其中有5 355项获得授权,授权率较低;目前已经失效的专利有7 848项,其中4 359项专利的失效原因是"专利申请公布后的视为撤回",即主要为申请人自动放弃;专利维持寿命大都较短,3年以上、5年以上、8年以上的专利数量分别为4 949、3 980、2 070项。专利法律状态信息对抗癌药物制造企业专利申请的基本信息具有重要的补充作用,在衡量研发差距和专利质量等方面尤为重要,值得深入研究。

OBJECTIVE： To provide reference for patent approval, the difference of R＆D and patent quality measurement in anticancer drug manufacturers. METHODS： Anticancer drug patent approved in China was taken as the research object in this pa- per. The legal status of anticancer drug patent approved in China were searched from patent information service platform of China Intellectual Property Right Net during Apr. 1st, 1985--Jun. 29th, 2012 and analyzed mainly in three aspects of patent authoriza- tion, patent invalidation and patent life. RESULTS ＆ CONCLUSIONS： Among 17 065 items of anticancer drugs patents approved in China, 5 355 items have got authorized, with a low proportion; 7 848 items have been already invalid at present, among which 4 359 items become invalid because of patent application being deemed to be withdrawn, that is mainly for the applicant surrender; patents are mainly maintained for a short period, and only 4 949 items are beyond 3 years, 3 980 items beyond 5 years and 2 070 items beyond 8 years. The legal status of patents is important for the supplement of the general information of patent approval, espe- cially for measuring the difference of R＆D and patent qualiW. It is worthy of further study.